195 related articles for article (PubMed ID: 24446130)
21. Somatic MED12 mutations in prostate cancer and uterine leiomyomas promote tumorigenesis through distinct mechanisms.
Kämpjärvi K; Kim NH; Keskitalo S; Clark AD; von Nandelstadh P; Turunen M; Heikkinen T; Park MJ; Mäkinen N; Kivinummi K; Lintula S; Hotakainen K; Nevanlinna H; Hokland P; Böhling T; Bützow R; Böhm J; Mecklin JP; Järvinen H; Kontro M; Visakorpi T; Taipale J; Varjosalo M; Boyer TG; Vahteristo P
Prostate; 2016 Jan; 76(1):22-31. PubMed ID: 26383637
[TBL] [Abstract][Full Text] [Related]
22. Subtype-Specific Tumor-Associated Fibroblasts Contribute to the Pathogenesis of Uterine Leiomyoma.
Wu X; Serna VA; Thomas J; Qiang W; Blumenfeld ML; Kurita T
Cancer Res; 2017 Dec; 77(24):6891-6901. PubMed ID: 29055020
[TBL] [Abstract][Full Text] [Related]
23. Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays.
Yatsenko SA; Mittal P; Wood-Trageser MA; Jones MW; Surti U; Edwards RP; Sood AK; Rajkovic A
Fertil Steril; 2017 Feb; 107(2):457-466.e9. PubMed ID: 27889101
[TBL] [Abstract][Full Text] [Related]
24. [MED12 gene mutations in women with uterine myoma].
Osinovskaya NS; Ivashchenko TE; Dolinskii AK; Sultanov IY; Ghimbovchi S; Hoffman E; Bezhenar VF; Baranov VS
Genetika; 2013 Dec; 49(12):1426-31. PubMed ID: 25438604
[TBL] [Abstract][Full Text] [Related]
25. Catechol-O-methyltransferase Val158Met polymorphism is associated with increased risk of multiple uterine leiomyomas either positive or negative for
Dzhemlikhanova LK; Efimova OA; Osinovskaya NS; Parfenyev SE; Niauri DA; Sultanov IY; Malysheva OV; Pendina AA; Shved NY; Ivashchenko TE; Yarmolinskaya MI; Kakhiani MI; Gorovaya EA; Tkachenko AN; Baranov VS
J Clin Pathol; 2017 Mar; 70(3):233-236. PubMed ID: 27491313
[TBL] [Abstract][Full Text] [Related]
26. MED12 exon 2 mutations in histopathological uterine leiomyoma variants.
Mäkinen N; Vahteristo P; Kämpjärvi K; Arola J; Bützow R; Aaltonen LA
Eur J Hum Genet; 2013 Nov; 21(11):1300-3. PubMed ID: 23443020
[TBL] [Abstract][Full Text] [Related]
27. Clonally related uterine leiomyomas are common and display branched tumor evolution.
Mehine M; Heinonen HR; Sarvilinna N; Pitkänen E; Mäkinen N; Katainen R; Tuupanen S; Bützow R; Sjöberg J; Aaltonen LA
Hum Mol Genet; 2015 Aug; 24(15):4407-16. PubMed ID: 25964426
[TBL] [Abstract][Full Text] [Related]
28. HMGA2 and the p19Arf-TP53-CDKN1A axis: a delicate balance in the growth of uterine leiomyomas.
Markowski DN; von Ahsen I; Nezhad MH; Wosniok W; Helmke BM; Bullerdiek J
Genes Chromosomes Cancer; 2010 Aug; 49(8):661-8. PubMed ID: 20544840
[TBL] [Abstract][Full Text] [Related]
29. Uterine fibroids: do we deal with more than one disease?
Markowski DN; Helmke BM; Bartnitzke S; Löning T; Bullerdiek J
Int J Gynecol Pathol; 2014 Nov; 33(6):568-72. PubMed ID: 25272295
[TBL] [Abstract][Full Text] [Related]
30. MED12 alterations in both human benign and malignant uterine soft tissue tumors.
Pérot G; Croce S; Ribeiro A; Lagarde P; Velasco V; Neuville A; Coindre JM; Stoeckle E; Floquet A; MacGrogan G; Chibon F
PLoS One; 2012; 7(6):e40015. PubMed ID: 22768200
[TBL] [Abstract][Full Text] [Related]
31. Vitamin D as an effective treatment in human uterine leiomyomas independent of mediator complex subunit 12 mutation.
Corachán A; Trejo MG; Carbajo-García MC; Monleón J; Escrig J; Faus A; Pellicer A; Cervelló I; Ferrero H
Fertil Steril; 2021 Feb; 115(2):512-521. PubMed ID: 33036796
[TBL] [Abstract][Full Text] [Related]
32. Antiproliferative effects by Let-7 repression of high-mobility group A2 in uterine leiomyoma.
Peng Y; Laser J; Shi G; Mittal K; Melamed J; Lee P; Wei JJ
Mol Cancer Res; 2008 Apr; 6(4):663-73. PubMed ID: 18403645
[TBL] [Abstract][Full Text] [Related]
33. Comparative analysis of AKT and the related biomarkers in uterine leiomyomas with MED12, HMGA2, and FH mutations.
Xie J; Ubango J; Ban Y; Chakravarti D; Kim JJ; Wei JJ
Genes Chromosomes Cancer; 2018 Oct; 57(10):485-494. PubMed ID: 29790226
[TBL] [Abstract][Full Text] [Related]
34. The study of MED12 gene mutations in uterine leiomyomas from Iranian patients.
Sadeghi S; Khorrami M; Amin-Beidokhti M; Abbasi M; Kamalian Z; Irani S; Omrani M; Azmoodeh O; Mirfakhraie R
Tumour Biol; 2016 Feb; 37(2):1567-71. PubMed ID: 26298726
[TBL] [Abstract][Full Text] [Related]
35. Clinical, pathologic, cytogenetic, and molecular profiling in self-identified black women with uterine leiomyomata.
Hayden MA; Ordulu Z; Gallagher CS; Quade BJ; Anchan RM; Middleton NR; Srouji SS; Stewart EA; Morton CC
Cancer Genet; 2018 Apr; 222-223():1-8. PubMed ID: 29666002
[TBL] [Abstract][Full Text] [Related]
36. Analysis of
Lee M; Cheon K; Chae B; Hwang H; Kim HK; Chung YJ; Song JY; Cho HH; Kim JH; Kim MR
Int J Med Sci; 2018; 15(2):124-128. PubMed ID: 29333096
[TBL] [Abstract][Full Text] [Related]
37. Selective genetic analysis of myoma pseudocapsule and potential biological impact on uterine fibroid medical therapy.
Di Tommaso S; Massari S; Malvasi A; Vergara D; Maffia M; Greco M; Tinelli A
Expert Opin Ther Targets; 2015 Jan; 19(1):7-12. PubMed ID: 25363374
[TBL] [Abstract][Full Text] [Related]
38. Aberrant expression of HMGA2 in uterine leiomyoma associated with loss of TSC2 tumor suppressor gene function.
Hunter DS; Klotzbücher M; Kugoh H; Cai SL; Mullen JP; Manfioletti G; Fuhrman U; Walker CL
Cancer Res; 2002 Jul; 62(13):3766-72. PubMed ID: 12097287
[TBL] [Abstract][Full Text] [Related]
39. Mutations in Exon 1 highlight the role of MED12 in uterine leiomyomas.
Kämpjärvi K; Park MJ; Mehine M; Kim NH; Clark AD; Bützow R; Böhling T; Böhm J; Mecklin JP; Järvinen H; Tomlinson IP; van der Spuy ZM; Sjöberg J; Boyer TG; Vahteristo P
Hum Mutat; 2014 Sep; 35(9):1136-41. PubMed ID: 24980722
[TBL] [Abstract][Full Text] [Related]
40. Frequency of MED12 Mutation in Relation to Tumor and Patient's Clinical Characteristics: a Meta-analysis.
He C; Nelson W; Li H; Xu YD; Dai XJ; Wang YX; Ding YB; Li YP; Li T
Reprod Sci; 2022 Feb; 29(2):357-365. PubMed ID: 33569750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
